✦ LIBER ✦

Similar Efficacy of Antiviral Therapy in Chronic Hepatitis C (CHC) Patients With Genotype 1 (G1) or Genotype 4 (G4). Results of a Large Nationwide Cohort Study

✍ Scribed by Anagnostou, Olga ;Manolakopoulos, Spilios ;Bakoyannis, Giorgos ;Papatheodoridis, George ;Raptopoulou-Gigi, Maria ;Gogos, Charalampos ;Karatapanis, Stylianos ;Karafoulidou, Anastasia ;Kitis, George ;Touloumi, Giota

Book ID: 122274803
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 308 KB
Volume: 140
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(11)63933-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1041 EFFICACY AND SAFETY OF ALBINTERFERO

1041 EFFICACY AND SAFETY OF ALBINTERFERON ALFA-2B IN COMBINATION WITH RIBAVIRIN IN TREATMENT- NAIVE, CHRONIC HEPATITIS C GENOTYPE 1 (CHC G1) PATIENTS

✍ Zeuzem, S.; Sulkowski, M.; Lawitz, E.; Rustgi, V.; Lurie, Y.; Grigorescu, M.; Mu 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Efficacy of interferon-based antiviral t

Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5: A meta-analysis of two large prospective clinical trials

✍ François D'Heygere; Christophe George; Hans Van Vlierberghe; Jochen Decaestecker 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 2 views

## Abstract The characteristics and response rate to pegylated interferon and ribavirin (PEG‐INF + RBV) of patients with chronic hepatitis C infected with genotype 5 are poorly documented. A meta‐analysis of two large phase III/IV prospective randomized clinical trials conducted in Belgium in patie

Safety and efficacy of protease inhibito

Safety and efficacy of protease inhibitor based combination therapy in a single-center “real-life” cohort of 110 patients with chronic hepatitis C genotype 1 infection

✍ Wehmeyer, Malte H; Eißing, Friederike; Jordan, Sabine; Röder, Claudia; Hennigs, 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 342 KB

A randomized, double-blind, multiple-dos

A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4

✍ Vince, Bradley; Hill, John M.; Lawitz, Eric J.; O’Riordan, William; Webster, Lyn 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 857 KB

1420 ASUNAPREVIR WITH PEGINTERFERON-ALFA

1420 ASUNAPREVIR WITH PEGINTERFERON-ALFA AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE-1 OR -4 CHRONIC HEPATITIS C: SVR24 RESULTS FROM A RANDOMIZED PHASE 2B STUDY (AI447016)

✍ Bronowicki, J.-P.; Ratziu, V.; Gadano, A.; Thuluvath, P.J.; Bessone, F.; Martore 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 77 KB

484 IMPACT OF LIVER FIBROSIS IN DEVELOPM

484 IMPACT OF LIVER FIBROSIS IN DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS TREATED WITH ANTIVIRAL THERAPY: LONG TERM FOLLOW UP STUDY

✍ Pellicelli, A.M.; Vignally, P.; Romano, M.; Miglioresi, L.; Mazzoni, E.; Mecenat 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 71 KB